Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Regulatory & Legal View source PDF Explain this filing

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹1206.80

prior close

₹1207.00

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%+0.2% vs market

Pharmaceuticals peers, median of 160sector-0.1%-0.1% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.1

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2-0.4+0.2-0.1-0.1

Next day

-3.0-1.9-1.1-0.9-2.1

-6.6-0.7-5.8-0.2-6.3

-4.1-0.7-3.5+0.3-4.5

-2.6+0.0-2.7+1.1-3.7

-3.0-0.1-3.0+0.2-3.2

-1.5+1.3-2.8+1.0-2.5

15d

-27.9-0.2-27.7-0.2-27.7

-29.8+3.0-32.8+1.7-31.5

-19.7+7.8-27.5+7.9-27.6

-25.9+9.1-35.0+8.1-34.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Natco Pharma has received a demand notice dated 12th May, 2026 from the National Pharmaceutical Pricing Authority (NPPA) directing the company to deposit ₹4,92,25,923 (approximately ₹4.92 crore), which includes alleged overcharge amount, penalty, and interest. The NPPA alleges that Natco overcharged for 2 drugs during the period April-2023 to November-2023, in violation of the Drugs Price Control Order, 2013 (DPCO). The company states there is no material impact on its financial, operational, or other activities. The disclosure was delayed due to technical and procedural issues in information flow, and the company has since complied with SEBI LODR requirements.

Likely market impact

While the demand amount of ~₹4.92 crore is material in absolute terms, the company has indicated no material financial impact. However, this represents a regulatory risk related to drug pricing compliance and could attract investor attention given the penalty component.